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ABSTRACT
Fusarium spp. cause infections only rarely in immunologically competent hosts, but disseminated
infection may occur in severely immunocompromised patients. Symptoms of disseminated infection are
persistent fever, despite broad-spectrum antibacterial and antifungal treatment, associated with skin
lesions, most commonly on the extremities, in 60–80% of patients. A mortality rate of 50–75% has been
reported for patients with disseminated fusariosis. Despite treatment failures, amphotericin B remains
the preferred drug, in part because of lack of alternatives. Voriconazole is a promising new agent, but
more clinical experience is required.
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The genus Fusarium comprises a large number of
species, most of which are common soil sapro-
phytes or plant pathogens [1,2]. The main char-
acteristic (Fig. 1) of the genus is the production of
multi-septate sickle-shaped macroconidia, with a
more or less pronounced foot cell [1]. In immu-
nologically competent hosts, Fusarium spp. cause
infections only rarely and, when they do, the
infections are mainly skin infections in surgical
wounds, burns or deep ulcers, nail infections or
keratitis [1–3]. Less commonly, these organisms
have been documented as aetiological agents in
localised tissue infections, including septic arth-
ritis, endophthalmitis, cystitis, peritonitis and
brain abscesses [1–3].
In contrast, in severely immunocompromised
patients, disseminated infection may occur.
Symptoms are persistent fever despite antibacte-
rial and antifungal treatment, with skin lesions in
60–80% of cases [1–4]. The lesions are seen most
commonly on extremities and appear as wide-
spread, violaceous or erythematous indurated
elements, sometimes progressing to necrosis
resembling ecthyma gangrenosum [2–5].
Most disseminated Fusarium infections have
been reported fromwarm climate zones. In Nordic
countries, disseminated Fusarium infections in
humans seem to be rare [1], with only a single
published case [5]. However, in our own hospitals,
four cases of blood culture-proven disseminated
fusariosis were diagnosed during 2000–2002
among patients with haematological diseases.
The ﬁrst case involved a 65-year-old woman
with acute lymphoblastic leukaemia who became
febrile during a second course of chemotherapy.
Broad-spectrum antibacterial agents were without
effect, and localised erythematous papular lesions
appeared on the extremities and face. Intravenous
amphotericin B (Ambisome), 300 mg daily, was
started. The fever resolved after treatment for
18 days, and the patient was discharged. Blood
cultures obtained 15 and 17 days after admission
yielded growth of Fusarium. Species identiﬁcation
was not performed.
The second case involved a 65-year-old man
receiving chemotherapy for relapsing chronic
lymphatic leukaemia. The patient became febrile
with lung inﬁltrates 7 days after admission, and
treatment with broad-spectrum antibacterial
agents and intravenous amphotericin B (Fungi-
zone), 50 mg daily, was commenced. Despite this,
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the fever continued and an erythematous indu-
rated area mimicking erysipelas was observed on
the right lower leg. Although treatment was
changed to intravenous amphotericin B (Amb-
isome), 300 mg daily, after 19 days, the patient
died after 23 days. Blood cultures yielded growth
of Fusarium, which was identiﬁed subsequently as
F. verticillioides (syn. F. moniliforme).
The third case involved a 52-year-old woman
with acute myeloid leukaemia who was admitted
with fever. Bone marrow examination revealed
disease relapse, and chemotherapy was initiated.
Broad-spectrum antibacterial treatment was
initiated at the time of admission. After 4 days,
painful localised erythematous papular lesions
were detected on the patient’s right foot sole and
both ear lobes. A blood culture taken after 16 days
yielded growth of Fusarium, and treatment with
intravenous amphotericin B (Ambisome), 300 mg
daily, was initiated. More erythematous papular
lesions developed on the neck and face, and the
fever continued, with progressive inﬁltrates in
the right lung. The patient died 14 days after the
initiation of amphotericin B following a cerebral
event. The Fusarium isolate was subsequently
identiﬁed as F. verticillioides (syn. F. moniliforme).
The fourth case involved a man aged 69 years
with non-Hodgkin’s lymphoma who was admit-
ted with persistent fever. As bone marrow exam-
ination revealed massive lymphoid inﬁltration,
the patient received three courses of chemother-
apy, in conjunction with intermittent broad-spec-
trum antibacterial treatment for neutropenia and
fever. Two weeks after the third course of che-
motherapy, the patient was again hospitalised
with fever, neutropenia and symptoms of respir-
atory tract infection. Broad-spectrum antibacterial
treatment and ﬂuconazole were initiated, but
when Fusarium was detected in blood cultures
after 4 days, the antimycotic treatment was
changed to intravenous amphotericin B (Amb-
isome), 200 mg daily. The patient stabilised ini-
tially, but remained deeply neutropenic and died
9 days after the initiation of amphotericin B with
a clinical picture of heart failure. The Fusarium
isolate was identiﬁed subsequently as F. solani.
A mortality rate of 50–75% has been reported
for patients with disseminated fusariosis [4,6,7],
which is in accordance with the survival of only
one of the four patients described above. The high
mortality rate presumably reﬂects both the infec-
tion and the serious underlying disease of this
group of patients. With the grave prognosis for
disseminated fusariosis and the lack of efﬁcient
antimycotic drugs, early detection and resolution
of neutropenia should be emphasised, possibly
aided by the use of exogenous growth factors
[1,4], and on removal of any primary infected
focus, such as infected nails [2] or intravenous
catheters [6–8], whenever possible. The portal of
entry was not established in the patients des-
cribed above. Three had pulmonary infection of
uncertain aetiology, and inhalation of spores
followed by pulmonary involvement has been
suggested previously as a likely mode of acqui-
sition of Fusarium infection [1–4,6].
Isolates of Fusarium can be resistant to most, if
not all, available antimycotic drugs [9–12]. A
discrepancy has been reported between microdi-
lution MICs and Etest endpoints for amphotericin
B [13], and more extensive investigations are
required to establish which method best predicts
the clinical outcome of treatment [3,11,12].
Despite the equivocal in-vitro susceptibility
results and treatment failures [7,10], amphotericin
B has remained the drug of choice for the
treatment of disseminated fusarial infections, as
there is a lack of alternatives [1,6]. Voriconazole is
a promising new agent [9,14–16], but more clinical
experience is required.
In countries with a warmer climate than Den-
mark, disseminated fusarial infections occur
throughout the year, but are frequently clustered
during rainy summer seasons [3,4,17]. In Den-
mark, precipitation is fairly constant, but as the
four infections described above occurred in the
summer months, the environmental temperature
Fig. 1. Typical microscopical appearance of Fusarium vert-
icillioides showing septate macroconidia.
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may also be important in determining the number
of aerial spores, and hence the risk of acquiring
the infection. It has been shown that the aerial
spore concentration of two other moulds, Alter-
naria and Cladosporium, is highest between June
and September [18]. Thus, even in northern
Europe, a clinical picture of persistent fever,
despite broad-spectrum antibacterial treatment,
in a severely immunocompromised patient with
skin lesions, or the growth of mould in a blood
culture, should suggest the possibility of Fusarium
infection.
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